Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.04 (overall 0.02) | 0.04 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 7275
Sealed predictions
- ZNF395 in dopamine neurons, braak+0.34 (p 0.373) → +0.12 (p 0.756)receipt 7282
Swarm cases
receipt 7282: ZNF395 in dopamine neurons, braak
- power
- full sample +0.20 (p 0.424, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.20 (p 0.429, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.13 (p 0.615, n 18). could be the mix.
- skeptic
- leave-one-out range +0.07 to +0.33, sign flips 0; without severely affected donors +0.20 (p 0.424, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.61 (p 0.0067, n 18) vs +0.20 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ZNF395 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ZNF395 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.50 p 0.076 (needs p < 2.9e-4)
Receipts
loading the receipts